Phase 2 N=80 Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Phase 2 N=10 Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Non-Small Cell Lung Cancer · Colorectal Cancer
Primary: Overall Response Rate — 1 Participants
Phase 2 N=39 Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Gastrointestinal Stromal Tumors
Primary: Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease — 52.6 Percentage of Participants
Phase 3 N=12 An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Solid Tumors
Primary: Number of Participants With Adverse Events of Grades 3 and 4 Severity — 6; 2; 1; 0 Participants
Phase 2 N=33 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Arm 1: Progression Free Survival (PFS) — 0; 0 Participants
Phase 3 N=570 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) Per Independent Central Radiology Review — 3.7; 3.6 Months
Phase 2 N=35 Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Determine the Objective Tumor Response Rate Following Treatment With TKI258 — 2; 22; 10 Participants
Phase 2 N=9 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
Phase 2 N=22 Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Phase 3 N=256 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Phase 2 N=22 TKI258 for Metastatic Inflammatory Breast Cancer Patients
Breast Cancer
Primary: Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants — 0; 0; 1 participants
Phase 2 N=10 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…
Phase 2 N=56 RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Gastrointestinal Cancer
Primary: Everolimus Maximum Tolerated Dose (MTD) [Phase I] — 10 mg daily for 4 weeks of a 4 week cycle
Phase 2 N=272 A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs) — 215; 31; 32; 16 Participants
Phase 2 N=106 LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Tumors With CDK4/6 Pathway Activation
Primary: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments — 0; 3; 16; 71 Participants
Phase 2 N=29 Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Advanced Gastrointestinal Stromal Tumors
Primary: Number of Participants With Non Progression at 4 Months — 3 Participants
Phase 2 N=146 BKM120 for Patients With PI3K-activated Tumors
PI3K Pathway Activated Tumors
Primary: Participant Clinical Benefit Response Rate — 15.1 percentage of participants
Phase 2 N=20 Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Phase 2 N=94 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants
Phase 2 N=50 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Thyroid Cancer
Primary: Median Progression Free Survival — 12.5 months
Phase 2 N=110 MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Phase 2 N=14 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
Phase 2 N=17 Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
Phase 2 N=21 Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Phase 3 N=492 Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Kidney Neoplasms
Primary: Progression Free Survival (PFS): First-Line Participants — 10.1; 6.5 months
Phase 2 N=165 A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Hepatocellular Carcinoma
Primary: Overall Survival - Overall Survival — 33; 39.4 Weeks
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
Phase 1 N=70 A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase — 14; 6; 7; 6 participants
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081